MDT Diabetes

Quote









There is more to this. Has anyone even thought about if this business/product will ever be good. At least two fixes that dont work. Why expect it to be different the third time. That is what is being said in that letter to our leader.
 
















Division is rotten from the top. Poor decisions being supported by a crumbling company that has doubled down on stupid. FDA only knows what they are allowed to see. They don’t have the time or resources to dive deep into the hidden corruption in the division. Less costly for Medtronic to cover it up than make the proper decisions to right the business.
 
















































anonymous said:
quality problem - lost share - warning letter - no approvals - further share loss - kill pipeline - buisness implodes - shutdown with indefinate patient support. Sound familiar to any other Medtronic buisness?
Click to expand...

wow you clearly don’t believe in the power of GUARDIAN CONNECT’s android approval- to MEET THE PATIENT WHERE THEYRE AT- along there diabetes journey.
 
























IPro was a brilliant product at the time. Leadership failed to evolve that product. Sensor technology then stalled while competitors invested heavily in CGM. Part of the failed Medtronic formula that got us to where we are today.
 
































“And in diabetes, we continue to lose share, predominantly in the U.S. Look, we're extremely focused on resolving our warning letter and bringing new products to the U.S. market although timing is difficult to predict. In December, CMS expanded coverage for our CGM sensors, including those integrated with our insulin pumps, and we're pleased that this will take effect for Medicare patients at the end of this month.”

In the international markets, we launched the 770G in Japan last month, making it the first hybrid closed loop system available in that country. And in Europe, we continue to see success and strong adoption of our 780G with the Guardian 4 sensor.
 
















Diabetes market is one of the biggest growth areas in med device. Yet Medtronic continually soils itself and can’t get out of its own way. Embarrassing. Doctors and patients don’t want our products anymore. Even as an employee I would use competitor products if I had to make that decision. That says a lot.
 
















Top Bottom
Back
Quote